Atlas Trials

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

Clinical trial NCT06702098 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06702098
Sponsor
Guangzhou Ruixin Biotechnological Co., LTD
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Acute Myeloid Leukemia (AML)
Start date
2024-11-25
Primary completion
2026-08-31
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.